Destiny Pharma plc news
Destiny Pharma plc (AIM:DEST), a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, today announces that Destiny Pharma’s CEO, Neil Clark, will present virtually at the upcoming HC Wainwright 24th Annual Global Investment Conference, being held on 12-14 September 2022 in New York and virtually.
The prese
Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, is pleased to announce the commencement of an Investigational New Drug (IND) enabling safety study with its novel XF-73 Dermal formulation.
This study is the second of two planned preclinical safety studies of the XF-73 Dermal formulation and will utilise a suite of preclinical services for interventional agent as
Targeting peak sales potential of $1 billion in the major markets
Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, is pleased to announce that it has now finalised plans for its Phase 3 studies for its late-stage clinical asset, XF-73 Nasal.
Highlights
- Discussions held with US and EU Regulators and Clinical Ke
- Particular support for decolonisation of pathogens which is the approach taken by its XF-73 Nasal programme
Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, today reports on the publication of findings from the US Food and Drug Administration (FDA) and US Centers for Disease Control (CDC) public workshop on considerations for the prevention of hos